Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Wu Capital
BioCentury | May 13, 2022
Emerging Company Profile
Nuvig: bringing immune homeostasis to inflammatory disease with a $47M A round
Backed by Novo Holdings and Platanus, Nuvig is designing proteins to selectively suppress active immune pathways
BioCentury | Jan 6, 2022
Finance
Jan. 5 Quick Takes: Eventide leads mega-round by Korro
Plus Saliogen raises $115M series B and updates from
BioCentury | Aug 18, 2021
Emerging Company Profile
Ranok: a chaperone-based approach to targeted degradation
Emerging Company Profile: Ranok has raised $40M to test whether alternative to PROTACs could have safety, dosing advantages
BioCentury | Nov 14, 2020
Emerging Company Profile
Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline
Emerging Company Profile: Inipharm will use its $35M series A to advance lead liver program through Phase I
BioCentury | Oct 20, 2020
Deals
Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta
Genesis and Genentech collaborate to identify drug candidates using AIStanford spinout and AI platform company Genesis Therapeutics Inc. entered into a collaboration agreement with the
BioCentury | Sep 10, 2020
Finance
Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO
Korro Bio’s $91.5 million series A round opens the door to new leadership for the Atlas-built RNA editing company, which has been led by Executive Chairman Nessan Bermingham since its
BioCentury | Jul 22, 2020
Finance
July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain
BioCentury | Mar 4, 2020
Finance
March 3 Quick Takes: Megarounds for Akouos, Element; plus venture rounds by Kahr, Primmune, Lipidio and Scipio and more
BioCentury | Jan 11, 2020
Financial News
Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy
BioCentury | Oct 11, 2019
Product Development
What’s next for neoantigens
The next act for neoantigens includes cell therapies and a broader range of targets
Items per page:
1 - 10 of 13